Promising CAR-T trial for kids with rare vasculitis pulled before start
NCT ID NCT06508346
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for children aged 5 to 25 who had not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-CD19 CAR-T cells
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Can a new drug tame vasculitis with fewer side effects?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Engineered immune cells take aim at autoimmune kidney diseases